Encision Reports Second Quarter Fiscal Year 2024 Results

Rhea-AI Summary

Encision Inc. (ECIA) Announces Fiscal 2024 Second Quarter Financial Results with $1.83M in Total Net Revenue and a Quarterly Net Loss of $7K. The company's product net revenue for the six months was $3.37M, with a six-month net loss of $148K. Encision's President and CEO, Gregory Trudel, discussed the challenges faced during the pandemic period and the slow rebound in demand for surgical procedures. The company is working on recreating service revenue with new partners and opportunities.

Positive

• Encision Inc. reported an increase in total net revenue compared to the year-ago quarter and six months, indicating resilience in a challenging market. The company's efforts to drive service revenue with new partners and opportunities demonstrate proactive measures to counter the impact of diminished demand for surgical procedures during the pandemic period.

Negative

• None.

BOULDER, CO / ACCESSWIRE / November 14, 2023 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today announced financial results for its fiscal 2024 second quarter that ended September 30, 2023.

The Company posted quarterly product net revenue of $1.75 million and service net revenue of $74 thousand, or total net revenue of $1.83 million for a quarterly net loss of $7 thousand, or $0.00 per diluted share. These results compare to product net revenue of $1.70 million and no service net revenue, or total net revenue of $1.70 million for a quarterly net loss of $279 thousand, or $(0.02) per diluted share, in the year-ago quarter. Gross margin on product net revenue was 47% in the fiscal 2024 second quarter and 49% in the fiscal 2023 second quarter.

The Company posted six months product net revenue of $3.37 million and service net revenue of $114 thousand, or total net revenue of $3.48 million for a six-month net loss of $148 thousand, or $(0.01) per diluted share. These results compare to product net revenue of $3.40 million and service net revenue of $459 thousand, or total net revenue of $3.86 million for a six-month net loss of $15 thousand, or $0.00 per diluted share, in the year-ago six months. Gross margin on product net revenue was 50% in the fiscal 2024 six months and 49% in the fiscal 2023 six months.

"The fiscal 2024 second quarter presented significant challenges for Encision and for the medical device market in general," said Gregory Trudel, President and CEO of Encision Inc. "The demand for surgical procedures was diminished during the pandemic period and its rebound has been a slow process. The market has seen a number of positive indicators for an increase in demand and Encision continues to drive toward them. The service revenue that we were able to drive in the previous year was very helpful and we are working to recreate that revenue stream with new partners and opportunities to collaborate on our foundational technologies."

Encision Inc. designs and markets a portfolio of high-performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, Colorado, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures. For additional information about all our products, please visit www.encision.com.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2023 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.
Unaudited Condensed Statements of Operations
(in thousands, except per share information)

		Three Months Ended								Six Months Ended
		September 30, 2023				September 30, 2022				September 30, 2023				September 30, 2022
Product revenue		$	1,752			$	1,704			$	3,366			$	3,400
Service revenue			74				--				114				459
Total revenue			1,826				1,704				3,480				3,859
Product cost of revenue			927				872				1,697				1,743
Service cost of revenue			37				--				58				--
Total cost of revenue			964				872				1,755				1,743
Gross profit			862				832				1,725				2,116
Operating expenses:
Sales and marketing			389				490				823				993
General and administrative			366				397				755				742
Research and development			101				223				269				393
Total operating expenses			856				1,110				1,847				2,128
Operating income (loss)			6				(278	)			(122	)			(12	)
Interest expense and other income, net			(13	)			(1	)			(26	)			(3	)
(Loss) before provision for income taxes			(7	)			(279	)			(148	)			(15	)
Provision for income taxes			--				--				--				--
Net (loss)		$	(7	)		$	(279	)		$	(148	)		$	(15	)
Net (loss) per share-basic and diluted		$	0.00			$	(0.02	)		$	(0.01	)		$	0.00
Weighted average shares-basic and diluted			11,770				11,752				11,770				11,735

Encision Inc.
Unaudited Condensed Balance Sheets
(in thousands)

		September 30, 2023				March 31, 2023
ASSETS
Cash		$	306			$	189
Accounts receivable			1,025				921
Inventories, net			1,642				1,899
Prepaid expenses			53				116
Total current assets			3,026				3,125
Equipment, net			272				303
Right of use asset			1,169				496
Patents, net			167				163
Other assets			55				47
Total assets		$	4,689			$	4,134
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable		$	300			$	253
Secured notes			44				44
Line of credit			339				177
Accrued compensation			167				218
Other accrued liabilities			41				85
Accrued lease liability			273				354
Total current liabilities			1,164				1,131
Secured notes			256				268
Accrued lease liability			896				240
Total liabilities			2,316				1,639
Common stock and additional paid-in capital			24,374				24,348
Accumulated (deficit)			(22,001	)			(21,853	)
Total shareholders' equity			2,373				2,495
Total liabilities and shareholders' equity		$	4,689			$	4,134

Encision Inc.
Unaudited Condensed Statements of Cash Flows
(in thousands)

		Six Months Ended
		September 30, 2023				September 30, 2022
Operating activities:
Net (loss)		$	(148	)		$	(15					)
Adjustments to reconcile net (loss) to cash (used in) operating activities:
Depreciation and amortization			44				41
Share-based compensation expense			26				25
Provision for inventory obsolescence, net			64				29
Changes in operating assets and liabilities:
Right of use asset, net			(97	)			(19					)
Accounts receivable			(104	)			33
Inventories			193				(303					)
Prepaid expenses and other assets			55				50
Accounts payable			47				(143					)
Accrued compensation and other accrued liabilities			(83	)			(36					)
Net cash (used in) operating activities			(3	)			(338					)
Investing activities:
Acquisition of property and equipment			--				(191					)
Patent costs			(17	)			(10					)
Net cash (used in) investing activities			(17	)			(201					)
Financing activities:
Net proceeds from options exercised			--				16
Borrowings from secured notes			137				110
Net cash provided by financing activities			137				126
Net increase (decrease) in cash			117			$	(413					)
Cash, beginning of period			189			$	950
Cash, end of period		$	306			$	537

SOURCE: Encision, Inc.

View source version on accesswire.com:
https://www.accesswire.com/802859/encision-reports-second-quarter-fiscal-year-2024-results

FAQ

What are Encision Inc.'s fiscal 2024 second quarter financial results?

Encision Inc. reported a total net revenue of $1.83 million with a quarterly net loss of $7 thousand, or $0.00 per diluted share.

What challenges did Encision Inc. face during the pandemic period?

The demand for surgical procedures was diminished during the pandemic period, leading to a slow rebound in demand. The company is working to recreate service revenue with new partners and opportunities.

Where is Encision Inc. based?

Encision Inc. is based in Boulder, Colorado and designs and markets high-performance surgical instrumentation with AEM technology.

What is AEM technology?

AEM technology, developed by Encision Inc., eliminates dangerous stray energy burns during minimally invasive procedures, thus advancing patient safety and surgical performance.